The EU has approved UCB’s Kygevi for rare disease TK2d, and Sanofi’s acute GvHD therapy Rezurock, in a pair of decisions announced this morning.
Pharma’s dealmaking tear; Blackstone raises record fund; Xolair energizes allergy research; and more
Welcome back to Endpoints Weekly! They say March comes in like a lion and out like a lamb, but two pharma giants made a roar

